
Management of Suspected Vaccine Induced Thrombosis and Thrombocytopenia at Guy's and St Thomas' Hospitals



- Consider thromboprophylaxis with non-heparin based anticoagulants
- Treatment options should be <u>discussed with the Thrombosis Consultant on call</u>
- Confirmed cases must be reported as soon as possible to the MHRA using the Yellow Card reporting scheme linked <u>here</u>

Vaccine induced thrombosis and thrombocytopenia is a potential rare complication occurring with 4-28 days of receiving the Oxford, AstraZeneca COVID-19 vaccine.

The thrombosis often includes cerebral venous sinus thrombosis, but cases of arterial thrombosis at other sites have been reported.

Typical laboratory features include Platelets <150x10⁹/L, significantly elevated D-dimer and low fibrinogen.

The syndrome has similarities to heparin induced thrombocytopenia, therefore it is important to <u>avoid all forms</u> <u>of heparin based anticoagulation and platelet transfusions</u> as they can potentially exacerbate thrombosis

The Thrombosis team at GSTT will prospectively collect information on confirmed cases, and provide to the MHRA and Public Health England